APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumour Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumour Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025192 pages

Choose your research edition.

Industry ResearchTumour Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumour Vaccine Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Tumour Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumour Vaccine Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumour Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Tumour Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumour Vaccine include Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals and Medigene AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Tumour Vaccine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumour Vaccine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumour Vaccine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Tumour Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumour Vaccine Segment by Company

Advaxis

Agenus Inc

Avidea Technologies

BioNTech

BrightPath Biotherapeutics

Genocea Biosciences Inc

Gritstone Bio

ISA Pharmaceuticals

Medigene AG

Moderna

Nouscom

Novogene

OSE Immunotherapeutics

Roche Holding AG

Vaccibody AS

Vaximm AG

ZIOPHARM Oncology

Pfizer

Eli Lilly and Company

Merck & Co Inc

Tumour Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Tumour Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Tumour Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumour Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumour Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumour Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Tumour Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumour Vaccine industry.

Chapter 3: Detailed analysis of Tumour Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumour Vaccinerevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tumour Vaccine Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Personalized Vaccine Table 3. Key Players of Off-the shelf Vaccine Table 4. Global Tumour Vaccine Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Gastrointestinal Cancer Table 6. Key Players of Lung Cancer Table 7. Key Players of Melanoma Cancer Table 8. Key Players of Brain Cancer Table 9. Key Players of Others Table 10. Global Tumour Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Tumour Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Tumour Vaccine Market Share by Region (2021-2026) Table 13. Global Tumour Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Tumour Vaccine Market Share by Region (2027-2032) Table 15. Tumour Vaccine Industry Trends Table 16. Tumour Vaccine Industry Drivers Table 17. Tumour Vaccine Industry Opportunities and Challenges Table 18. Tumour Vaccine Industry Restraints Table 19. Global Tumour Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Tumour Vaccine Revenue Market Share by Company (2021-2026) Table 21. Global Tumour Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Tumour Vaccine Key Company Head Office and Area Served Table 23. Global Tumour Vaccine Company, Product Type & Application Table 24. Global Tumour Vaccine Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Tumour Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Tumour Vaccine Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Tumour Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Tumour Vaccine Revenue Market Share by Type (2021-2026) Table 31. Global Tumour Vaccine Revenue Market Share by Type (2027-2032) Table 32. Global Tumour Vaccine Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Tumour Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Tumour Vaccine Revenue Market Share by Application (2021-2026) Table 36. Global Tumour Vaccine Revenue Market Share by Application (2027-2032) Table 37. Advaxis Company Information Table 38. Advaxis Business Overview Table 39. Advaxis Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Advaxis Tumour Vaccine Product Portfolio Table 41. Advaxis Recent Development Table 42. Agenus Inc Company Information Table 43. Agenus Inc Business Overview Table 44. Agenus Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Agenus Inc Tumour Vaccine Product Portfolio Table 46. Agenus Inc Recent Development Table 47. Avidea Technologies Company Information Table 48. Avidea Technologies Business Overview Table 49. Avidea Technologies Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Avidea Technologies Tumour Vaccine Product Portfolio Table 51. Avidea Technologies Recent Development Table 52. BioNTech Company Information Table 53. BioNTech Business Overview Table 54. BioNTech Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. BioNTech Tumour Vaccine Product Portfolio Table 56. BioNTech Recent Development Table 57. BrightPath Biotherapeutics Company Information Table 58. BrightPath Biotherapeutics Business Overview Table 59. BrightPath Biotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. BrightPath Biotherapeutics Tumour Vaccine Product Portfolio Table 61. BrightPath Biotherapeutics Recent Development Table 62. Genocea Biosciences Inc Company Information Table 63. Genocea Biosciences Inc Business Overview Table 64. Genocea Biosciences Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Genocea Biosciences Inc Tumour Vaccine Product Portfolio Table 66. Genocea Biosciences Inc Recent Development Table 67. Gritstone Bio Company Information Table 68. Gritstone Bio Business Overview Table 69. Gritstone Bio Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Gritstone Bio Tumour Vaccine Product Portfolio Table 71. Gritstone Bio Recent Development Table 72. ISA Pharmaceuticals Company Information Table 73. ISA Pharmaceuticals Business Overview Table 74. ISA Pharmaceuticals Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. ISA Pharmaceuticals Tumour Vaccine Product Portfolio Table 76. ISA Pharmaceuticals Recent Development Table 77. Medigene AG Company Information Table 78. Medigene AG Business Overview Table 79. Medigene AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Medigene AG Tumour Vaccine Product Portfolio Table 81. Medigene AG Recent Development Table 82. Moderna Company Information Table 83. Moderna Business Overview Table 84. Moderna Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Moderna Tumour Vaccine Product Portfolio Table 86. Moderna Recent Development Table 87. Nouscom Company Information Table 88. Nouscom Business Overview Table 89. Nouscom Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Nouscom Tumour Vaccine Product Portfolio Table 91. Nouscom Recent Development Table 92. Novogene Company Information Table 93. Novogene Business Overview Table 94. Novogene Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Novogene Tumour Vaccine Product Portfolio Table 96. Novogene Recent Development Table 97. OSE Immunotherapeutics Company Information Table 98. OSE Immunotherapeutics Business Overview Table 99. OSE Immunotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. OSE Immunotherapeutics Tumour Vaccine Product Portfolio Table 101. OSE Immunotherapeutics Recent Development Table 102. Roche Holding AG Company Information Table 103. Roche Holding AG Business Overview Table 104. Roche Holding AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. Roche Holding AG Tumour Vaccine Product Portfolio Table 106. Roche Holding AG Recent Development Table 107. Vaccibody AS Company Information Table 108. Vaccibody AS Business Overview Table 109. Vaccibody AS Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Vaccibody AS Tumour Vaccine Product Portfolio Table 111. Vaccibody AS Recent Development Table 112. Vaximm AG Company Information Table 113. Vaximm AG Business Overview Table 114. Vaximm AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 115. Vaximm AG Tumour Vaccine Product Portfolio Table 116. Vaximm AG Recent Development Table 117. ZIOPHARM Oncology Company Information Table 118. ZIOPHARM Oncology Business Overview Table 119. ZIOPHARM Oncology Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 120. ZIOPHARM Oncology Tumour Vaccine Product Portfolio Table 121. ZIOPHARM Oncology Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 125. Pfizer Tumour Vaccine Product Portfolio Table 126. Pfizer Recent Development Table 127. Eli Lilly and Company Company Information Table 128. Eli Lilly and Company Business Overview Table 129. Eli Lilly and Company Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 130. Eli Lilly and Company Tumour Vaccine Product Portfolio Table 131. Eli Lilly and Company Recent Development Table 132. Merck & Co Inc Company Information Table 133. Merck & Co Inc Business Overview Table 134. Merck & Co Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 135. Merck & Co Inc Tumour Vaccine Product Portfolio Table 136. Merck & Co Inc Recent Development Table 137. North America Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 138. North America Tumour Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 139. North America Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 140. North America Tumour Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 141. North America Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Tumour Vaccine Market Size by Country (2021-2026) Table 143. North America Tumour Vaccine Market Size by Country (2027-2032) Table 144. Europe Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 145. Europe Tumour Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 146. Europe Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 147. Europe Tumour Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 148. Europe Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Tumour Vaccine Market Size by Country (2021-2026) Table 150. Europe Tumour Vaccine Market Size by Country (2027-2032) Table 151. China Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 152. China Tumour Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 153. China Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 154. China Tumour Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 155. Asia Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 156. Asia Tumour Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 157. Asia Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 158. Asia Tumour Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 159. Asia Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Tumour Vaccine Market Size by Country (2021-2026) Table 161. Asia Tumour Vaccine Market Size by Country (2027-2032) Table 162. South America, Middle East & Africa Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 163. South America, Middle East & Africa Tumour Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 164. South America, Middle East & Africa Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 165. South America, Middle East & Africa Tumour Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 166. South America, Middle East & Africa Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. South America, Middle East & Africa Tumour Vaccine Market Size by Country (2021-2026) Table 168. South America, Middle East & Africa Tumour Vaccine Market Size by Country (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Tumour Vaccine Product Image Figure 2. Global Tumour Vaccine Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Tumour Vaccine Market Share by Type: 2025 VS 2032 Figure 4. Personalized Vaccine Image Figure 5. Off-the shelf Vaccine Image Figure 6. Global Tumour Vaccine Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Tumour Vaccine Market Share by Application: 2025 VS 2032 Figure 8. Gastrointestinal Cancer Image Figure 9. Lung Cancer Image Figure 10. Melanoma Cancer Image Figure 11. Brain Cancer Image Figure 12. Others Image Figure 13. Global Tumour Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 15. Global Tumour Vaccine Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Tumour Vaccine Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Tumour Vaccine Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Tumour Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Tumour Vaccine Revenue Market Share by Type (2021-2032) Figure 22. Global Tumour Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Tumour Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 25. North America Tumour Vaccine Market Share by Type (2021-2032) Figure 26. North America Tumour Vaccine Market Share by Application (2021-2032) Figure 27. North America Tumour Vaccine Market Share by Country (2021-2032) Figure 28. United States Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 29. Canada Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 31. Europe Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 32. Europe Tumour Vaccine Market Share by Type (2021-2032) Figure 33. Europe Tumour Vaccine Market Share by Application (2021-2032) Figure 34. Europe Tumour Vaccine Market Share by Country (2021-2032) Figure 35. Germany Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 36. France Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 38. Italy Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 39. Russia Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 41. China Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 42. China Tumour Vaccine Market Share by Type (2021-2032) Figure 43. China Tumour Vaccine Market Share by Application (2021-2032) Figure 44. Asia Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 45. Asia Tumour Vaccine Market Share by Type (2021-2032) Figure 46. Asia Tumour Vaccine Market Share by Application (2021-2032) Figure 47. Asia Tumour Vaccine Market Share by Country (2021-2032) Figure 48. Japan Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 52. India Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 53. Australia Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Tumour Vaccine Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Tumour Vaccine Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Tumour Vaccine Market Share by Country (2021-2032) Figure 58. Brazil Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 63. UAE Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 65. Chile Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Advaxis
  • Agenus Inc
  • Avidea Technologies
  • BioNTech
  • BrightPath Biotherapeutics
  • Genocea Biosciences Inc
  • Gritstone Bio
  • ISA Pharmaceuticals
  • Medigene AG
  • Moderna
  • Nouscom
  • Novogene
  • OSE Immunotherapeutics
  • Roche Holding AG
  • Vaccibody AS
  • Vaximm AG
  • ZIOPHARM Oncology
  • Pfizer
  • Eli Lilly and Company
  • Merck & Co Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Tumour Vaccine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Personalized Vaccine
  5. 1.2.3 Off-the shelf Vaccine
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Tumour Vaccine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Gastrointestinal Cancer
  9. 1.3.3 Lung Cancer
  10. 1.3.4 Melanoma Cancer
  11. 1.3.5 Brain Cancer
  12. 1.3.6 Others
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Tumour Vaccine Growth Trends by Region
  15. 1.5.1 Global Tumour Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Tumour Vaccine Market Size by Region (2021-2026)
  17. 1.5.3 Tumour Vaccine Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Tumour Vaccine Market Dynamics
  1. 2.1 Tumour Vaccine Industry Trends
  2. 2.2 Tumour Vaccine Industry Drivers
  3. 2.3 Tumour Vaccine Industry Opportunities and Challenges
  4. 2.4 Tumour Vaccine Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Tumour Vaccine Revenue by Company (2021-2026)
  2. 3.2 Global Tumour Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Tumour Vaccine Key Company Head office and Area Served
  4. 3.4 Global Tumour Vaccine Company, Product Type & Application
  5. 3.5 Global Tumour Vaccine Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Tumour Vaccine Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Tumour Vaccine Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Tumour Vaccine Tier 1, Tier 2, and Tier 3
4 Tumour Vaccine Market by Type
  1. 4.1 Global Tumour Vaccine Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Tumour Vaccine Market Size by Type (2021-2032)
  3. 4.3 Global Tumour Vaccine Market Size Share by Type (2021-2032)
5 Tumour Vaccine Market by Application
  1. 5.1 Global Tumour Vaccine Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Tumour Vaccine Market Size by Application (2021-2032)
  3. 5.3 Global Tumour Vaccine Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Advaxis
  2. 6.1.1 Advaxis Company Information
  3. 6.1.2 Advaxis Business Overview
  4. 6.1.3 Advaxis Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Advaxis Tumour Vaccine Product Portfolio
  6. 6.1.5 Advaxis Recent Developments
  7. 6.2 Agenus Inc
  8. 6.2.1 Agenus Inc Company Information
  9. 6.2.2 Agenus Inc Business Overview
  10. 6.2.3 Agenus Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Agenus Inc Tumour Vaccine Product Portfolio
  12. 6.2.5 Agenus Inc Recent Developments
  13. 6.3 Avidea Technologies
  14. 6.3.1 Avidea Technologies Company Information
  15. 6.3.2 Avidea Technologies Business Overview
  16. 6.3.3 Avidea Technologies Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Avidea Technologies Tumour Vaccine Product Portfolio
  18. 6.3.5 Avidea Technologies Recent Developments
  19. 6.4 BioNTech
  20. 6.4.1 BioNTech Company Information
  21. 6.4.2 BioNTech Business Overview
  22. 6.4.3 BioNTech Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 BioNTech Tumour Vaccine Product Portfolio
  24. 6.4.5 BioNTech Recent Developments
  25. 6.5 BrightPath Biotherapeutics
  26. 6.5.1 BrightPath Biotherapeutics Company Information
  27. 6.5.2 BrightPath Biotherapeutics Business Overview
  28. 6.5.3 BrightPath Biotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 BrightPath Biotherapeutics Tumour Vaccine Product Portfolio
  30. 6.5.5 BrightPath Biotherapeutics Recent Developments
  31. 6.6 Genocea Biosciences Inc
  32. 6.6.1 Genocea Biosciences Inc Company Information
  33. 6.6.2 Genocea Biosciences Inc Business Overview
  34. 6.6.3 Genocea Biosciences Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Genocea Biosciences Inc Tumour Vaccine Product Portfolio
  36. 6.6.5 Genocea Biosciences Inc Recent Developments
  37. 6.7 Gritstone Bio
  38. 6.7.1 Gritstone Bio Company Information
  39. 6.7.2 Gritstone Bio Business Overview
  40. 6.7.3 Gritstone Bio Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Gritstone Bio Tumour Vaccine Product Portfolio
  42. 6.7.5 Gritstone Bio Recent Developments
  43. 6.8 ISA Pharmaceuticals
  44. 6.8.1 ISA Pharmaceuticals Company Information
  45. 6.8.2 ISA Pharmaceuticals Business Overview
  46. 6.8.3 ISA Pharmaceuticals Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 ISA Pharmaceuticals Tumour Vaccine Product Portfolio
  48. 6.8.5 ISA Pharmaceuticals Recent Developments
  49. 6.9 Medigene AG
  50. 6.9.1 Medigene AG Company Information
  51. 6.9.2 Medigene AG Business Overview
  52. 6.9.3 Medigene AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Medigene AG Tumour Vaccine Product Portfolio
  54. 6.9.5 Medigene AG Recent Developments
  55. 6.10 Moderna
  56. 6.10.1 Moderna Company Information
  57. 6.10.2 Moderna Business Overview
  58. 6.10.3 Moderna Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Moderna Tumour Vaccine Product Portfolio
  60. 6.10.5 Moderna Recent Developments
  61. 6.11 Nouscom
  62. 6.11.1 Nouscom Company Information
  63. 6.11.2 Nouscom Business Overview
  64. 6.11.3 Nouscom Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Nouscom Tumour Vaccine Product Portfolio
  66. 6.11.5 Nouscom Recent Developments
  67. 6.12 Novogene
  68. 6.12.1 Novogene Company Information
  69. 6.12.2 Novogene Business Overview
  70. 6.12.3 Novogene Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Novogene Tumour Vaccine Product Portfolio
  72. 6.12.5 Novogene Recent Developments
  73. 6.13 OSE Immunotherapeutics
  74. 6.13.1 OSE Immunotherapeutics Company Information
  75. 6.13.2 OSE Immunotherapeutics Business Overview
  76. 6.13.3 OSE Immunotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 OSE Immunotherapeutics Tumour Vaccine Product Portfolio
  78. 6.13.5 OSE Immunotherapeutics Recent Developments
  79. 6.14 Roche Holding AG
  80. 6.14.1 Roche Holding AG Company Information
  81. 6.14.2 Roche Holding AG Business Overview
  82. 6.14.3 Roche Holding AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Roche Holding AG Tumour Vaccine Product Portfolio
  84. 6.14.5 Roche Holding AG Recent Developments
  85. 6.15 Vaccibody AS
  86. 6.15.1 Vaccibody AS Company Information
  87. 6.15.2 Vaccibody AS Business Overview
  88. 6.15.3 Vaccibody AS Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Vaccibody AS Tumour Vaccine Product Portfolio
  90. 6.15.5 Vaccibody AS Recent Developments
  91. 6.16 Vaximm AG
  92. 6.16.1 Vaximm AG Company Information
  93. 6.16.2 Vaximm AG Business Overview
  94. 6.16.3 Vaximm AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Vaximm AG Tumour Vaccine Product Portfolio
  96. 6.16.5 Vaximm AG Recent Developments
  97. 6.17 ZIOPHARM Oncology
  98. 6.17.1 ZIOPHARM Oncology Company Information
  99. 6.17.2 ZIOPHARM Oncology Business Overview
  100. 6.17.3 ZIOPHARM Oncology Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 ZIOPHARM Oncology Tumour Vaccine Product Portfolio
  102. 6.17.5 ZIOPHARM Oncology Recent Developments
  103. 6.18 Pfizer
  104. 6.18.1 Pfizer Company Information
  105. 6.18.2 Pfizer Business Overview
  106. 6.18.3 Pfizer Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Pfizer Tumour Vaccine Product Portfolio
  108. 6.18.5 Pfizer Recent Developments
  109. 6.19 Eli Lilly and Company
  110. 6.19.1 Eli Lilly and Company Company Information
  111. 6.19.2 Eli Lilly and Company Business Overview
  112. 6.19.3 Eli Lilly and Company Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Eli Lilly and Company Tumour Vaccine Product Portfolio
  114. 6.19.5 Eli Lilly and Company Recent Developments
  115. 6.20 Merck & Co Inc
  116. 6.20.1 Merck & Co Inc Company Information
  117. 6.20.2 Merck & Co Inc Business Overview
  118. 6.20.3 Merck & Co Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Merck & Co Inc Tumour Vaccine Product Portfolio
  120. 6.20.5 Merck & Co Inc Recent Developments
7 North America
  1. 7.1 North America Tumour Vaccine Market Size (2021-2032)
  2. 7.2 North America Tumour Vaccine Market Size by Type
  3. 7.2.1 North America Tumour Vaccine Market Size by Type (2021-2026)
  4. 7.2.2 North America Tumour Vaccine Market Size by Type (2027-2032)
  5. 7.2.3 North America Tumour Vaccine Market Share by Type (2021-2032)
  6. 7.3 North America Tumour Vaccine Market Size by Application
  7. 7.3.1 North America Tumour Vaccine Market Size by Application (2021-2026)
  8. 7.3.2 North America Tumour Vaccine Market Size by Application (2027-2032)
  9. 7.3.3 North America Tumour Vaccine Market Share by Application (2021-2032)
  10. 7.4 North America Tumour Vaccine Market Size by Country
  11. 7.4.1 North America Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Tumour Vaccine Market Size by Country (2021-2026)
  13. 7.4.3 North America Tumour Vaccine Market Size by Country (2027-2032)
  14. 7.4.4 North America Tumour Vaccine Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Tumour Vaccine Market Size (2021-2032)
  2. 8.2 Europe Tumour Vaccine Market Size by Type
  3. 8.2.1 Europe Tumour Vaccine Market Size by Type (2021-2026)
  4. 8.2.2 Europe Tumour Vaccine Market Size by Type (2027-2032)
  5. 8.2.3 Europe Tumour Vaccine Market Share by Type (2021-2032)
  6. 8.3 Europe Tumour Vaccine Market Size by Application
  7. 8.3.1 Europe Tumour Vaccine Market Size by Application (2021-2026)
  8. 8.3.2 Europe Tumour Vaccine Market Size by Application (2027-2032)
  9. 8.3.3 Europe Tumour Vaccine Market Share by Application (2021-2032)
  10. 8.4 Europe Tumour Vaccine Market Size by Country
  11. 8.4.1 Europe Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Tumour Vaccine Market Size by Country (2021-2026)
  13. 8.4.3 Europe Tumour Vaccine Market Size by Country (2027-2032)
  14. 8.4.4 Europe Tumour Vaccine Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Tumour Vaccine Market Size (2021-2032)
  2. 9.2 China Tumour Vaccine Market Size by Type
  3. 9.2.1 China Tumour Vaccine Market Size by Type (2021-2026)
  4. 9.2.2 China Tumour Vaccine Market Size by Type (2027-2032)
  5. 9.2.3 China Tumour Vaccine Market Share by Type (2021-2032)
  6. 9.3 China Tumour Vaccine Market Size by Application
  7. 9.3.1 China Tumour Vaccine Market Size by Application (2021-2026)
  8. 9.3.2 China Tumour Vaccine Market Size by Application (2027-2032)
  9. 9.3.3 China Tumour Vaccine Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Tumour Vaccine Market Size (2021-2032)
  2. 10.2 Asia Tumour Vaccine Market Size by Type
  3. 10.2.1 Asia Tumour Vaccine Market Size by Type (2021-2026)
  4. 10.2.2 Asia Tumour Vaccine Market Size by Type (2027-2032)
  5. 10.2.3 Asia Tumour Vaccine Market Share by Type (2021-2032)
  6. 10.3 Asia Tumour Vaccine Market Size by Application
  7. 10.3.1 Asia Tumour Vaccine Market Size by Application (2021-2026)
  8. 10.3.2 Asia Tumour Vaccine Market Size by Application (2027-2032)
  9. 10.3.3 Asia Tumour Vaccine Market Share by Application (2021-2032)
  10. 10.4 Asia Tumour Vaccine Market Size by Country
  11. 10.4.1 Asia Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Tumour Vaccine Market Size by Country (2021-2026)
  13. 10.4.3 Asia Tumour Vaccine Market Size by Country (2027-2032)
  14. 10.4.4 Asia Tumour Vaccine Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Tumour Vaccine Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Tumour Vaccine Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Tumour Vaccine Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Tumour Vaccine Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Tumour Vaccine Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Tumour Vaccine Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Tumour Vaccine Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Tumour Vaccine Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Tumour Vaccine Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Tumour Vaccine Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Tumour Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Tumour Vaccine Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Tumour Vaccine Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Tumour Vaccine Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst